Due to current legislation regarding weight loss drugs, Medicare Part D or Part C plans with drug coverage may only cover Zepbound for treating obstructive sleep apnea (OSA). However, the Centers ...

If you or a loved one has sleep apnea, you may be considering different treatment options. A new treatment you may hear about is Zepbound (tirzepatide). In December 2024, Zepbound became the ...

Learn how and where to inject Zepbound and where to get additional help. Plus, get tips for injecting the drug at home and ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

also known as Mounjaro or Zepbound. It's FDA approved to manage diabetes and obesity. Now, UC San Diego researchers have gotten it approved as the first effective drug therapy for sleep apnea.

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

and we continue to think Novo and Lilly will gain Medicare obesity drug coverage via overlapping indications with time, such as Zepbound’s recent approval in sleep apnea and semaglutide’s ...

Advertisement Advertisement The Biden proposal would have included coverage of Wegovy and Zepbound to treat obesity under Medicare Part D for Medicare Advantage. “While today’s announcement ...

"We are proud to announce that LifeMD now accepts Medicare Fee-For-Service for qualifying virtual primary care, including such care provided in our weight management program – an important step ...

“It's called GLP one receptor,” said Atul Malhotra, MD from the UC San Diego School of Medicine. It’s already FDA-approved to manage diabetes and obesity — now, researchers at UC San Diego have gotten ...